Developments in the world of artificial intelligence continue to accelerate at a rapid pace. Our November issue of Pharmaceutical Executive explores a few of those that are starting to deliver measurable gains for the industry.
Our coverage here at Pharmaceutical Executive has been all over the rise of artificial intelligence (AI) in life sciences and healthcare for the last couple years or so. Our November issue is no exception. But, as mentioned on this page before, our focus is on advancing the discussion and information as much as possible. We want to chronicle for you, our reader, the developments, innovations, and new strategies that are stretching the field beyond the hype and into the realm of practical application internally, for your operations, and in changing medicine and patient care.
Offering such value, we hope, is the slate of various tech and AI-focused content featured in this month’s issue. That includes our Executive Profile, where editor Mike Hollan spoke with Noam Solomon, CEO and co-founder of Immunai, a biotech that specializes in combining machine learning and biology to transform efforts in oncology . The company, notably, has a partnership with AstraZeneca. And leading off a trio of features in our technology-themed section is a guest piece from leaders with Sanofi and Aily Labs, an AI software company, on leveraging “enterprise AI” in daily pharma practice to deliver savings and efficiency gains “that are impossible through traditional methods.”
“C-suite pharma executives must champion large-scale AI adoption at scale and build a clear roadmap for democratizing this technology enterprise-wide,” the authors write.
The article details, via a use case, AI’s ability to provide “decision intelligence” by aggregating massive and complex data points into “bite-size” insights. Info can then be extracted to help predict such value drivers as R&D costs, clinical trial enrollment timelines, and a program’s probability of success. Those are just a few examples. The authors note that the intention of these tools is to integrate across business functions—with the goal of breaking down silos and offering a “360-degree operational view.”
As far as measurable gains for industry so far, according to the authors, AI initiatives at Sanofi have translated to $300 million in savings by predicting and mitigating 80% of low inventory risks. Broadly, as well, they cite a PwC report that finds that pharma companies that adopt AI across their organizations have the potential to double their operating profits and gain an additional $254 billion in those profits globally by 2030.
AI developments until then will likely continue to be fast and furious. We look forward to sharing the ones that matter most with you. Thanks for reading.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Yescarta Demonstrates Promise in Treating Relapsed/Refractory Large B-Cell Lymphoma
December 9th 2024Real-world evidence from the largest analysis of second-line treatment with Yescarta in 2022-2023 demonstrated a high overall survival rate in patients with relapsed/refractory large b-cell lymphoma.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.